Recently, affiliates in North Carolina, Pennsylvania, Michigan, New York and Kansas all made the announcement, with other plans like Highmark and Care Network of Michigan only allowing its use with prior approval. The announcements largely affect commercial plans.
“We have evaluated the published peer-reviewed literature on the evidence of Aduhelm’s safety and effectiveness in treating Alzheimer’s disease,” Independence Blue Cross said in its statement. “We have concluded that it does not sufficiently show that the drug’s clinical benefits outweigh its harms or that it reduces progression of the disease.”
The announcements echo a lack of research and evidence of benefits, earning the drug the experimental/investigational label and disqualifying it from coverage.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
